ondasdechoque.org
PT-BR

Keloids and hypertrophic scars · Lab and clinical study · 2024

Can shockwave help keloids and raised scars?

This review gathered 12 studies on shockwave for keloids and raised (hypertrophic) scars. Keloids improved with shockwave alone and with steroid injections, with no clear difference, and adding shockwave to injections improved scar scores more. Several studies reported thinner, less itchy or less painful raised scars.

Possible early help for raised scars
keloid trials
2
studies of raised (hypertrophic) scars
7
lab studies in rabbits or cells
3

Good to know: Studies used different treatment plans and scar measures.

Gili N, Micallef Stafrace K, Laybats F, et al. Cureus, 2024 · Read the paper ↗

The treatment

Keloid clinical protocols
Wang: 3 sessions over 6 weeks; lesion-area-dependent impulses (area in cm² × 8, minimum 500); 0.11 mJ/mm², 4 Hz; generator type not specified, dermPACE. Kim: weekly for 10 weeks; 500 impulses/cm²; 0.29 mJ/mm²; 250 pulses/min (4.2 Hz); generator type not specified, dermPACE. Intralesional triamcinolone was the comparator in Wang (10 mg, three sessions at two-weekly intervals) and was given to both groups in Kim (10 mg per 1 cm² of lesion, four sessions at three-weekly intervals).
Hypertrophic scar clinical protocol range
Raw Table 5 lists 3–10 sessions, one per week (Fioramonti and Zaghloul: two per week for 6 weeks), 100–3,000 pulses/session or 30–50, 100 (1,000–2,000/session) or 350 ± 10 pulses/cm², EFD 0.037–0.30 mJ/mm² when reported, and 4–6 Hz. Zaghloul energy/frequency are not stated. Focused/radial type is mostly unspecified; one Joo row is labeled focused. Do not homogenize these regimens.
Chuangsuwanich 2022
One session weekly for 6 weeks; 350±10 pulses/cm²; 0.1 mJ/mm²; 4 Hz; focused/radial status not specified; Dermagold 100.
Fioramonti 2012
Two sessions weekly for 6 weeks; 100 pulses; 0.037 mJ/mm²; 4 Hz; modality not specified; Evotron.
Moorgart 2020
One session weekly for 10 weeks; 30–50 pulses/cm²; 0.25 mJ/mm²; 6 Hz; modality not specified; Duolith-SD1 T-Top.
Zaghloul 2016
Two sessions weekly for 6 weeks; 2,500–3,000 pulses; energy, frequency, modality and instrument not specified.
Lee 2021
One session weekly for 6 weeks; 100 pulses/cm² (1,000–2,000 per session); 0.05–0.30 mJ/mm²; 4 Hz; modality not specified; Duolith SD-1.
Joo 2020
One session weekly for 4 weeks; 100 pulses/cm² (1,000–2,000 per session); 0.05–0.30 mJ/mm²; 4 Hz; modality not specified; Duolith SD-1.
Joo 2018
One session weekly for 3 weeks; 100 pulses/cm² (1,000–2,000 per session); 0.05–0.20 mJ/mm²; 4 Hz; focused; Duolith SD-1.
Zhao 2018 [36] — rabbits
One session weekly for 4 weeks; 500 pulses; low-energy ESWT 0.1 mJ/mm² and high-energy 0.2 mJ/mm²; 8 Hz; modality not specified; Swiss DolClast Classic.
Cui 2018 [37] — cell culture
One session; 1,000 pulses; 0.03, 0.1 or 0.3 mJ/mm²; 4 Hz; focused; Duolith SD-1.
Zhao 2018 [38] — rabbits
One session weekly for 4 weeks; 500 pulses; low-energy 0.1 mJ/mm² and high-energy 0.18 mJ/mm²; 8 Hz; radial; Swiss DolClast Classic.

Who took part

People with keloids or raised scars in 2 keloid trials and 7 scar studies, plus 3 studies in rabbits or cells.

Side effects

The review does not report side effects.

All the numbers and the full appraisal
FROM THE FULL PAPER

What the full paper reports.

Systematic review of pathological scars: 2 keloid randomized trials; 7 hypertrophic-scar clinical studies; 3 preclinical studies (2 rabbit experiments, 1 fibroblast culture). Human and experimental samples are not additive.

Study-level narrative synthesis9 reported outcomes
01
As reported by the included study

Included clinical and preclinical reports

Study-level narrative synthesis Narrative synthesis

The review reports 12 articles: 2 keloid RCTs and 10 hypertrophic-scar reports, comprising 7 clinical studies and 3 preclinical studies (2 rabbit experiments and 1 fibroblast-culture study). Human and experimental units are distinct and must not be combined. Table 4 has a participant-count inconsistency for Lee et al. (2021): 25 ESWT + 28 control = 53, although the table states 48.

Analysis details and source

Review-level extraction; underlying primary papers were not independently inspected. No pooled estimate is claimed. Human clinical and preclinical findings remain separate.

02
As reported by the included study

Keloid ESWT versus steroid injection

Study-level narrative synthesis Narrative synthesis

Wang et al. randomized 39 patients (22 ESWT, 17 intralesional steroid). Both groups improved lesion area/volume, pain and POSAS scores from baseline, but between-group tests were nonsignificant: pain p=0.429, POSAS patient p=0.55, observer p=0.25. These results do not establish equivalence.

Analysis details and source

Review-level extraction; underlying primary papers were not independently inspected. No pooled estimate is claimed. Human clinical and preclinical findings remain separate.

03
As reported by the included study

ESWT added to steroid for keloids

Study-level narrative synthesis Narrative synthesis

Kim et al. compared ESWT plus steroid (n=20) with steroid alone (n=20). VSS declined 56.13%±18.12% versus 40.15%±14.09%; the greater decline in the adjunct group was significant (p=0.003). Lesion length, width and height also decreased in both groups, with greater percentage reductions reported for ESWT plus steroid. This tests add-on therapy, not steroid replacement.

Analysis details and source

Review-level extraction; underlying primary papers were not independently inspected. No pooled estimate is claimed. Human clinical and preclinical findings remain separate.

04
As reported by the included study

Hypertrophic-scar thickness

Study-level narrative synthesis Narrative synthesis

Zaghloul et al. reported mean ultrasound thickness reduction of 2.86 mm (42.55%) with ESWT versus 0.8 mm (12%) with placebo; between-group p=0.0001. Joo et al. and Lee et al. also reported significant thickness reduction (p=0.018 and p=0.03, respectively). The review does not provide confidence intervals or complete arm summaries in the accessible text.

Analysis details and source

Review-level extraction; underlying primary papers were not independently inspected. No pooled estimate is claimed. Human clinical and preclinical findings remain separate.

05
As reported by the included study

Hypertrophic-scar scores and appearance

Study-level narrative synthesis Narrative synthesis

Findings varied by instrument: Chuangsuwanich and Moorgart reported significant POSAS improvements; Zaghloul reported VSS mean decrease 4.25 (48.57%). Joo found vascularity improvement (p=0.0015) but no significant total VSS change (p=0.19). Erythema findings conflicted (Lee p=0.03; Chuangsuwanich p=0.7; Moorgart nonsignificant); melanin index was nonsignificant in Chuangsuwanich (p=0.87) and Lee (p=0.62). The review also reports Moorgart vertical elasticity improvement, with no significant TEWL change; Lee sebum and erythema improved but TEWL, skin elasticity and melanin did not; Chuangsuwanich erythema and melanin did not improve.

Analysis details and source

Review-level extraction; underlying primary papers were not independently inspected. No pooled estimate is claimed. Human clinical and preclinical findings remain separate.

06
As reported by the included study

Hypertrophic-scar symptoms and function

Study-level narrative synthesis Narrative synthesis

Joo et al. (2020) reported significant pain improvement (p=0.001), and Joo et al. (2018) reported itch-frequency/duration/severity/consequence improvements (all p<0.05). Significant improvement was reported in two hand-function subtasks; other subtasks did not change significantly. The text cites this hand-function result to reference [35] (Joo 2018), but Tables 4 and 8 list hand function under Joo et al. (2020) [34]. Fioramonti reported subjective VAS appearance improvement without statistical analysis. These findings come from different studies and should not be treated as one combined effect.

Analysis details and source

Review-level extraction; underlying primary papers were not independently inspected. No pooled estimate is claimed. Human clinical and preclinical findings remain separate.

07
As reported by the included study

Preclinical scar biology and morphology

Study-level narrative synthesis Narrative synthesis

Two rabbit experiments and one fibroblast-culture study reported changes in scar elevation index, collagen arrangement, fibroblast density, TGF-β1, α-SMA, extracellular-matrix markers, Smad signaling, wrinkles or hemoglobin. These are animal/cellular findings, not clinical patient outcomes. Table 8 says the 2018 rabbit study found no significant effect on scar diameter, area, elevation/volume or melanin. Table 8 specifies that Zhao [36] found significant changes in collagen-fiber arrangement, fibroblast density and scar-elevation index; Cui [37] reported significant TGF-β1, α-SMA, collagen I/III, fibronectin and protein-expression changes; Zhao [38] reported significant hemoglobin, TGF-β/Smad and wrinkle findings, but null diameter, area, elevation/volume and melanin results.

Analysis details and source

Review-level extraction; underlying primary papers were not independently inspected. No pooled estimate is claimed. Human clinical and preclinical findings remain separate.

08
As reported by the included study

Reported ESWT protocols

Study-level narrative synthesis Narrative synthesis

Keloid regimens: Wang, 3 sessions over 6 weeks, lesion-area-dependent impulses (area cm² ×8; minimum 500), 0.11 mJ/mm², 4 Hz; Kim, weekly for 10 weeks, 500 impulses/cm², 0.29 mJ/mm², 250 pulses/min (4.2 Hz). Hypertrophic clinical protocols varied from 3 to 10 weeks (3 to 12 sessions); raw Tables 5 and 7 specify study-level doses, including one study with energy/frequency not reported. Most devices were not identified as radial/focused.

Analysis details and source

Review-level extraction; underlying primary papers were not independently inspected. No pooled estimate is claimed. Human clinical and preclinical findings remain separate.

09
As reported by the included study

Adverse events

Study-level narrative synthesis Narrative synthesis

The accessible main text provides no systematic adverse-event results for the scar trials. Its discussion lists known steroid-injection risks but does not quantify ESWT harms. Do not infer that ESWT was harmless.

Analysis details and source

Review-level extraction; underlying primary papers were not independently inspected. No pooled estimate is claimed. Human clinical and preclinical findings remain separate.

Study-specific outcomes as classified in Table 812 reported outcomes
10
As reported in the review; no common timepoint stated in Table 8

Wang et al. (2018), keloid RCT

Study-specific outcomes as classified in Table 8 Narrative result; no effect estimate supplied in this table

Significant changes were reported in collagen I, Masson’s trichrome, collagen III and MMP-13. No statistically significant improvement was reported in blood-flow perfusion, cell activity, proliferation, apoptosis/concentration, angiogenesis, or proliferative, anti-inflammatory or apoptosis biomarkers. Patient and observer POSAS functional outcomes improved; total lesion surface area and volume decreased; patient and observer POSAS aesthetic outcomes improved.

Analysis details and source

Table 8 qualitative significance statements are reproduced without inventing p values or effect magnitudes. Clinical and preclinical evidence is kept separate.

11
As reported in the review; no common timepoint stated in Table 8

Kim et al. (2020), keloid RCT

Study-specific outcomes as classified in Table 8 Narrative result; no effect estimate supplied in this table

Table 8 states biological outcomes were not assessed. Lesion length, width, height and VSS improved significantly.

Analysis details and source

Table 8 qualitative significance statements are reproduced without inventing p values or effect magnitudes. Clinical and preclinical evidence is kept separate.

12
As reported in the review; no common timepoint stated in Table 8

Chuangsuwanich et al. (2022), hypertrophic scar RCT

Study-specific outcomes as classified in Table 8 Narrative result; no effect estimate supplied in this table

Patient and observer POSAS functional outcomes and POSAS aesthetic outcomes improved significantly; erythema and melanin indices did not improve significantly.

Analysis details and source

Table 8 qualitative significance statements are reproduced without inventing p values or effect magnitudes. Clinical and preclinical evidence is kept separate.

13
As reported in the review; no common timepoint stated in Table 8

Fioramonti et al. (2012), hypertrophic scar, prospective observational study

Study-specific outcomes as classified in Table 8 Narrative result; no effect estimate supplied in this table

Appearance improved on VAS, with no statistical analysis available. Biological and functional outcomes were not assessed.

Analysis details and source

Table 8 qualitative significance statements are reproduced without inventing p values or effect magnitudes. Clinical and preclinical evidence is kept separate.

14
As reported in the review; no common timepoint stated in Table 8

Moorgart et al. (2020), hypertrophic scar RCT

Study-specific outcomes as classified in Table 8 Narrative result; no effect estimate supplied in this table

Vertical elasticity and patient/observer POSAS functional outcomes improved significantly. Transepidermal water loss (TEWL) did not improve significantly. POSAS aesthetic outcomes improved; color did not change significantly.

Analysis details and source

Table 8 qualitative significance statements are reproduced without inventing p values or effect magnitudes. Clinical and preclinical evidence is kept separate.

15
As reported in the review; no common timepoint stated in Table 8

Zaghloul et al. (2016), hypertrophic scar RCT

Study-specific outcomes as classified in Table 8 Narrative result; no effect estimate supplied in this table

Table 8 reports significant improvement in ultrasound-measured scar thickness and VSS; biological and functional outcomes were not assessed.

Analysis details and source

Table 8 qualitative significance statements are reproduced without inventing p values or effect magnitudes. Clinical and preclinical evidence is kept separate.

16
As reported in the review; no common timepoint stated in Table 8

Lee et al. (2021), hypertrophic scar RCT

Study-specific outcomes as classified in Table 8 Narrative result; no effect estimate supplied in this table

Sebum, scar thickness and erythema improved significantly. TEWL, skin elasticity and melanin index did not improve significantly; functional outcomes were not assessed.

Analysis details and source

Table 8 qualitative significance statements are reproduced without inventing p values or effect magnitudes. Clinical and preclinical evidence is kept separate.

17
As reported in the review; no common timepoint stated in Table 8

Joo et al. (2020), hypertrophic scar RCT

Study-specific outcomes as classified in Table 8 Narrative result; no effect estimate supplied in this table

Skin vascularity, pain, scar thickness and VAS improved significantly; Table 8 lists hand function as improved without stating significance. Scar pigmentation and total VSS did not improve significantly.

Analysis details and source

Table 8 qualitative significance statements are reproduced without inventing p values or effect magnitudes. Clinical and preclinical evidence is kept separate.

18
As reported in the review; no common timepoint stated in Table 8

Joo et al. (2018), hypertrophic scar RCT

Study-specific outcomes as classified in Table 8 Narrative result; no effect estimate supplied in this table

NRS, laser-Doppler blood-perfusion imaging, 5-D Itch Scale and Leuven Itch Scale improved significantly. Aesthetic outcomes were not assessed.

Analysis details and source

Table 8 qualitative significance statements are reproduced without inventing p values or effect magnitudes. Clinical and preclinical evidence is kept separate.

19
As reported in the review; no common timepoint stated in Table 8

Zhao et al. (2018) [36], preclinical rabbit study

Study-specific outcomes as classified in Table 8 Narrative result; no effect estimate supplied in this table

Collagen-fiber arrangement, fibroblast density and scar-elevation index improved significantly. These are not clinical outcomes in people.

Analysis details and source

Table 8 qualitative significance statements are reproduced without inventing p values or effect magnitudes. Clinical and preclinical evidence is kept separate.

20
As reported in the review; no common timepoint stated in Table 8

Cui et al. (2018) [37], preclinical fibroblast culture

Study-specific outcomes as classified in Table 8 Narrative result; no effect estimate supplied in this table

TGF-β1, α-SMA, collagen I and III, fibronectin and protein expression improved significantly. Functional and aesthetic outcomes were not assessed.

Analysis details and source

Table 8 qualitative significance statements are reproduced without inventing p values or effect magnitudes. Clinical and preclinical evidence is kept separate.

21
As reported in the review; no common timepoint stated in Table 8

Zhao et al. (2018) [38], preclinical rabbit study

Study-specific outcomes as classified in Table 8 Narrative result; no effect estimate supplied in this table

Hemoglobin, TGF-β1, Smad2, Smad3, Smad7 and scar wrinkles improved significantly. Scar diameter, area, elevation/volume and melanin did not improve significantly. These are preclinical findings.

Analysis details and source

Table 8 qualitative significance statements are reproduced without inventing p values or effect magnitudes. Clinical and preclinical evidence is kept separate.

How treatment was delivered
Keloid clinical protocols

Wang: 3 sessions over 6 weeks; lesion-area-dependent impulses (area in cm² × 8, minimum 500); 0.11 mJ/mm², 4 Hz; generator type not specified, dermPACE. Kim: weekly for 10 weeks; 500 impulses/cm²; 0.29 mJ/mm²; 250 pulses/min (4.2 Hz); generator type not specified, dermPACE. Intralesional triamcinolone was the comparator in Wang (10 mg, three sessions at two-weekly intervals) and was given to both groups in Kim (10 mg per 1 cm² of lesion, four sessions at three-weekly intervals).

Hypertrophic scar clinical protocol range

Raw Table 5 lists 3–10 sessions, one per week (Fioramonti and Zaghloul: two per week for 6 weeks), 100–3,000 pulses/session or 30–50, 100 (1,000–2,000/session) or 350 ± 10 pulses/cm², EFD 0.037–0.30 mJ/mm² when reported, and 4–6 Hz. Zaghloul energy/frequency are not stated. Focused/radial type is mostly unspecified; one Joo row is labeled focused. Do not homogenize these regimens.

Chuangsuwanich 2022

One session weekly for 6 weeks; 350±10 pulses/cm²; 0.1 mJ/mm²; 4 Hz; focused/radial status not specified; Dermagold 100.

Fioramonti 2012

Two sessions weekly for 6 weeks; 100 pulses; 0.037 mJ/mm²; 4 Hz; modality not specified; Evotron.

Moorgart 2020

One session weekly for 10 weeks; 30–50 pulses/cm²; 0.25 mJ/mm²; 6 Hz; modality not specified; Duolith-SD1 T-Top.

Zaghloul 2016

Two sessions weekly for 6 weeks; 2,500–3,000 pulses; energy, frequency, modality and instrument not specified.

Lee 2021

One session weekly for 6 weeks; 100 pulses/cm² (1,000–2,000 per session); 0.05–0.30 mJ/mm²; 4 Hz; modality not specified; Duolith SD-1.

Joo 2020

One session weekly for 4 weeks; 100 pulses/cm² (1,000–2,000 per session); 0.05–0.30 mJ/mm²; 4 Hz; modality not specified; Duolith SD-1.

Joo 2018

One session weekly for 3 weeks; 100 pulses/cm² (1,000–2,000 per session); 0.05–0.20 mJ/mm²; 4 Hz; focused; Duolith SD-1.

Zhao 2018 [36] — rabbits

One session weekly for 4 weeks; 500 pulses; low-energy ESWT 0.1 mJ/mm² and high-energy 0.2 mJ/mm²; 8 Hz; modality not specified; Swiss DolClast Classic.

Cui 2018 [37] — cell culture

One session; 1,000 pulses; 0.03, 0.1 or 0.3 mJ/mm²; 4 Hz; focused; Duolith SD-1.

Zhao 2018 [38] — rabbits

One session weekly for 4 weeks; 500 pulses; low-energy 0.1 mJ/mm² and high-energy 0.18 mJ/mm²; 8 Hz; radial; Swiss DolClast Classic.

HARMS & TOLERABILITY

The review does not present systematic adverse-event results for ESWT in the included scar trials. Do not infer safety from silence. Steroid risks discussed by authors are contextual, not comparative harm data.

LIMITS OF THE ANALYSIS

Only 12 articles were included; studies had small samples and heterogeneous designs, protocols and outcomes. Long-term follow-up was limited and publication bias was not formally assessed.

Table 4 reports 48 subjects for Lee et al. (2021), but lists 25 ESWT and 28 control, totaling 53. The review does not resolve this discrepancy.

Keloid monotherapy results reported no significant between-group differences, while discussion calls outcomes comparable; no equivalence margin or precision interval is supplied. Add-on ESWT was a different comparison.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Only 12 articles were included; studies had small samples and heterogeneous designs, protocols and outcomes. Long-term follow-up was limited and publication bias was not formally assessed.
  • Table 4 reports 48 subjects for Lee et al. (2021), but lists 25 ESWT and 28 control, totaling 53. The review does not resolve this discrepancy.
  • Keloid monotherapy results reported no significant between-group differences, while discussion calls outcomes comparable; no equivalence margin or precision interval is supplied. Add-on ESWT was a different comparison.
Research review

Source-linked critical reading

Systematic review of human and preclinical studies

Reading depthMaterial consulted
Technical source record

Complete article and raw Tables 1–8 read including all study rows, protocols, numeric outcomes and discrepancies; all four captions and limitations/discussion/conclusions checked.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Design

Systematic literature review using PRISMA methods; 12 included articles, with no meta-analysis. Risk-of-bias tools varied by trial design and species.

Evidence base

Two keloid RCTs (39 and 40 patients); seven hypertrophic-scar clinical reports plus three preclinical studies (two rabbit experiments and one cell culture). Do not combine human and preclinical units.

Intervention

Clinical regimens varied by scar and study. Keloid protocols included 3 sessions over 6 weeks at 0.11 mJ/mm² and weekly sessions for 10 weeks at 0.29 mJ/mm². Hypertrophic protocols and details varied; see reported ranges and missing fields.

Comparators

Keloid studies compared ESWT with intralesional steroid or ESWT plus steroid with steroid alone. Hypertrophic studies used sham/control or before-after designs.

Findings

Keloid monotherapy and steroid groups both improved, without significant between-group differences. Adding ESWT to steroid improved VSS more than steroid alone (56.13%±18.12% vs 40.15%±14.09%; p=0.003). Hypertrophic findings varied by score/feature; thickness decreased in several studies. Animal/cell markers are not patient outcomes. The nine clinical and three preclinical rows of Table 8 are now represented separately, including study-level positive and null biological, functional and aesthetic findings; the seven hypertrophic-scar and three preclinical dose rows are transcribed individually from Tables 5 and 7.

Between-group interpretation

Nonsignificant ESWT-versus-steroid results do not prove equivalence. Add-on ESWT versus steroid alone tests augmentation, not replacement. One table contains a participant-count inconsistency (Lee: 25+28 versus stated 48).

Harms

No systematic trial-level ESWT adverse-event results are available in the main text. Lack of reporting is not evidence of no harms.

Limitations

Small evidence base, varied designs/outcomes/protocols, limited long-term follow-up, no meta-analysis and publication bias not formally assessed. Table 4 count for Lee et al. is internally inconsistent.

Applicability

Potentially relevant to symptom and scar-feature research, but effect certainty, recurrence, durability and optimal protocol remain unclear. Experimental biology cannot establish patient benefit.

Research needs

Larger preregistered trials should separate keloids from hypertrophic scars, standardize scar measures and protocol, report between-group estimates/intervals and harms, and follow recurrence over time.

THE ORIGINAL SOURCE

Read the original article.

The Role of Extracorporeal Shock Wave Therapy in Keloids and Hypertrophic Scars: A Systematic Review.

Gili N, Micallef Stafrace K, Laybats F, Mifsud T. · Cureus · 2024

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →